2SEVENTY BIO INC (TSVT) Fundamental Analysis & Valuation

NASDAQ:TSVT • US9013841070

Current stock price

5 USD
+0.01 (+0.2%)
At close:
5 USD
0 (0%)
After Hours:

This TSVT fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. TSVT Profitability Analysis

1.1 Basic Checks

  • TSVT had negative earnings in the past year.
  • In the past year TSVT has reported a negative cash flow from operations.
  • TSVT had negative earnings in each of the past 5 years.
  • TSVT had a negative operating cash flow in each of the past 5 years.
TSVT Yearly Net Income VS EBIT VS OCF VS FCFTSVT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M

1.2 Ratios

  • TSVT has a better Return On Assets (-11.94%) than 83.81% of its industry peers.
  • The Return On Equity of TSVT (-27.16%) is better than 79.54% of its industry peers.
Industry RankSector Rank
ROA -11.94%
ROE -27.16%
ROIC N/A
ROA(3y)-29.71%
ROA(5y)-33.2%
ROE(3y)-64.75%
ROE(5y)-87.29%
ROIC(3y)N/A
ROIC(5y)N/A
TSVT Yearly ROA, ROE, ROICTSVT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600

1.3 Margins

  • Looking at the Gross Margin, with a value of 52.43%, TSVT is in the better half of the industry, outperforming 77.22% of the companies in the same industry.
  • In the last couple of years the Gross Margin of TSVT has declined.
  • TSVT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 52.43%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-18.09%
GM growth 5Y-10.87%
TSVT Yearly Profit, Operating, Gross MarginsTSVT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. TSVT Health Analysis

2.1 Basic Checks

  • TSVT does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • TSVT has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, TSVT has more shares outstanding
  • There is no outstanding debt for TSVT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
TSVT Yearly Shares OutstandingTSVT Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
TSVT Yearly Total Debt VS Total AssetsTSVT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

  • TSVT has an Altman-Z score of -1.30. This is a bad value and indicates that TSVT is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of TSVT (-1.30) is comparable to the rest of the industry.
  • There is no outstanding debt for TSVT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.3
ROIC/WACCN/A
WACC10.02%
TSVT Yearly LT Debt VS Equity VS FCFTSVT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 200M -200M

2.3 Liquidity

  • TSVT has a Current Ratio of 4.67. This indicates that TSVT is financially healthy and has no problem in meeting its short term obligations.
  • TSVT has a Current ratio (4.67) which is in line with its industry peers.
  • TSVT has a Quick Ratio of 4.67. This indicates that TSVT is financially healthy and has no problem in meeting its short term obligations.
  • TSVT has a Quick ratio of 4.67. This is comparable to the rest of the industry: TSVT outperforms 53.56% of its industry peers.
Industry RankSector Rank
Current Ratio 4.67
Quick Ratio 4.67
TSVT Yearly Current Assets VS Current LiabilitesTSVT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. TSVT Growth Analysis

3.1 Past

  • TSVT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 72.14%, which is quite impressive.
  • Looking at the last year, TSVT shows a very negative growth in Revenue. The Revenue has decreased by -62.28% in the last year.
  • TSVT shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -3.09% yearly.
EPS 1Y (TTM)72.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)-62.28%
Revenue growth 3Y-11.43%
Revenue growth 5Y-3.09%
Sales Q2Q%84.29%

3.2 Future

  • TSVT is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 20.56% yearly.
  • TSVT is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 12.75% yearly.
EPS Next Y58.41%
EPS Next 2Y33.7%
EPS Next 3Y30.96%
EPS Next 5Y20.56%
Revenue Next Year42.31%
Revenue Next 2Y24.94%
Revenue Next 3Y18.14%
Revenue Next 5Y12.75%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
TSVT Yearly Revenue VS EstimatesTSVT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M 200M
TSVT Yearly EPS VS EstimatesTSVT Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -5 -10

More info and screens

Find the best growth stocksShow best growing peers

1

4. TSVT Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for TSVT. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TSVT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TSVT Price Earnings VS Forward Price EarningsTSVT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TSVT Per share dataTSVT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

  • TSVT's earnings are expected to grow with 30.96% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.7%
EPS Next 3Y30.96%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. TSVT Dividend Analysis

5.1 Amount

  • TSVT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

TSVT Fundamentals: All Metrics, Ratios and Statistics

2SEVENTY BIO INC

NASDAQ:TSVT (5/12/2025, 8:00:01 PM)

After market: 5 0 (0%)

5

+0.01 (+0.2%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-08
Earnings (Next)08-05
Inst Owners89.58%
Inst Owner Change0%
Ins Owners4.73%
Ins Owner Change0%
Market Cap266.15M
Revenue(TTM)37.86M
Net Income(TTM)-57.25M
Analysts47.5
Price Target5.1 (2%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-7.06%
Min EPS beat(2)-36.88%
Max EPS beat(2)22.77%
EPS beat(4)2
Avg EPS beat(4)33.02%
Min EPS beat(4)-36.88%
Max EPS beat(4)168.1%
EPS beat(8)5
Avg EPS beat(8)20.21%
EPS beat(12)8
Avg EPS beat(12)15.79%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-44.21%
Min Revenue beat(2)-76.66%
Max Revenue beat(2)-11.76%
Revenue beat(4)0
Avg Revenue beat(4)-34.98%
Min Revenue beat(4)-76.66%
Max Revenue beat(4)-11.76%
Revenue beat(8)1
Avg Revenue beat(8)-19.01%
Revenue beat(12)3
Avg Revenue beat(12)2.13%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-23.08%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-15.65%
EPS NY rev (1m)0%
EPS NY rev (3m)-14.28%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)5.4%
Revenue NY rev (1m)0%
Revenue NY rev (3m)4.24%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 7.03
P/FCF N/A
P/OCF N/A
P/B 1.26
P/tB 1.3
EV/EBITDA N/A
EPS(TTM)-1.12
EYN/A
EPS(NY)-0.24
Fwd EYN/A
FCF(TTM)-1.61
FCFYN/A
OCF(TTM)-1.6
OCFYN/A
SpS0.71
BVpS3.96
TBVpS3.85
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -11.94%
ROE -27.16%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 52.43%
FCFM N/A
ROA(3y)-29.71%
ROA(5y)-33.2%
ROE(3y)-64.75%
ROE(5y)-87.29%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-18.09%
GM growth 5Y-10.87%
F-Score3
Asset Turnover0.08
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 9.96%
Cap/Sales 1.87%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.67
Quick Ratio 4.67
Altman-Z -1.3
F-Score3
WACC10.02%
ROIC/WACCN/A
Cap/Depr(3y)114.29%
Cap/Depr(5y)126.28%
Cap/Sales(3y)13.55%
Cap/Sales(5y)17.11%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)72.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y58.41%
EPS Next 2Y33.7%
EPS Next 3Y30.96%
EPS Next 5Y20.56%
Revenue 1Y (TTM)-62.28%
Revenue growth 3Y-11.43%
Revenue growth 5Y-3.09%
Sales Q2Q%84.29%
Revenue Next Year42.31%
Revenue Next 2Y24.94%
Revenue Next 3Y18.14%
Revenue Next 5Y12.75%
EBIT growth 1Y54.56%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year58.95%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y52.58%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y49.06%
OCF growth 3YN/A
OCF growth 5YN/A

2SEVENTY BIO INC / TSVT Fundamental Analysis FAQ

What is the ChartMill fundamental rating of 2SEVENTY BIO INC (TSVT) stock?

ChartMill assigns a fundamental rating of 3 / 10 to TSVT.


What is the valuation status for TSVT stock?

ChartMill assigns a valuation rating of 1 / 10 to 2SEVENTY BIO INC (TSVT). This can be considered as Overvalued.


Can you provide the profitability details for 2SEVENTY BIO INC?

2SEVENTY BIO INC (TSVT) has a profitability rating of 2 / 10.


Can you provide the financial health for TSVT stock?

The financial health rating of 2SEVENTY BIO INC (TSVT) is 6 / 10.